The global market for pulmonary arterial hypertension is estimated to have a significant CAGR during the forecast period. The market is mainly driven due to the increasing prevalence of pulmonary arterial hypertension, government initiatives for research on drugs across the globe. Excessive consumption of alcohol and tobacco has severe health effects on the human body. Moreover, an unhealthy lifestyle, increasing alcohol consumption further increases the risk of various arterial disease such as pulmonary arterial hypertension. According to the CDC (Centers for Disease Control and Prevention), around 88,000 US citizens lose their lives every year due to alcohol abuse. Long-term health complications of alcohol include increased heart rate, increased BP (blood pressure), weakened heart muscles, irregular heartbeat that give rise to various cardiovascular and neurological disorders, such as pulmonary arterial hypertension

Segmental Outlook  

The global pulmonary arterial hypertension market is segregated on the basis of drug type including Endothelin Receptor Antagonists (ERA), Calcium Channel Blockers, Prostacyclin and Prostacyclin Analogs, Phosphodiesterase 5 (PDE-5) and others (Soluble Guanylate Cyclase (SGC) Stimulators).

Global Pulmonary arterial hypertension Market Share by Drug Type, 2018(%)

Global Pulmonary arterial hypertension market to be driven by Prostacyclin and Prostacyclin Analogs

The prostacyclin and prostacyclin analogs segment projected to have considerable market share in the global pulmonary arterial hypertension market. The growing use of prostacyclin oral drugs for the treatment of pulmonary arterial hypertension further provides considerable share to the segment. The Prostacyclin is a participant of the prostaglandin group of bioactive lipids. The prostacyclin significant role is in the cardiovascular system, where it is released by vascular endothelial cells, serving as a potent vasodilator and inhibitor of platelet aggregation. Moreover, Calcium Channel Blockers are projected to have significant growth in the global pulmonary arterial hypertension market during the forecast period.  

Regional Outlook 

Geographically, the global pulmonary arterial hypertension market is further classified into North America, Europe, Asia-Pacific and the Rest of the World.North America is projected to have a significant market share in the global market.The growing incidence of pulmonary arterial hypertension owing to aging populations, increased per capita healthcare expenditure and the presence of major market players are driving the market in this region.US Census Bureau estimated that people aged over 65 years represented around 15% of the total population of the country in 2014. This share is further estimated to reach 21% by 2030 and 24% by 2060.Europe is one of the key contributors to the market. UK, Germany, Spain, Italy, France are the key countries that contribute to the market growth. 

Global Pulmonary arterial hypertension Market Growth, by Region 2019-2025

Asia-Pacific to hold a considerable growth in the global Pulmonary arterial hypertension market

Geographically, Asia-Pacific is projected to have a significant market growth in the global pulmonary arterial hypertension market. The major economies such as China, Australia, Japan, South Korea, India, and Singapore are significantly contributing to the growth of the market during the forecast period. An aging population coupled with the increasing number of pulmonary arterial hypertension cases are the major factor that contributes to the market growth. As the population of India and China grows, its expanding share of older adults is particularly notable. The United Nations Population Division projects that India’s population age 50 years and older will reach 34% by 2050. Between 2010 and 2050, the share of people aged over 65 and older is expected to increase from 5% to 14%, while the share in the oldest age group (80 and older) will triple from 1% to 3%. Furthermore, Beijing State Council Information Office is projecting that the country's aged population (above 60 years old) will reach 255 million by 2020. The country’s aging population will grow at an average rate of 6.4 million a year.

Market Players Outlook

The key players in the Pulmonary arterial hypertension market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Johnson & Johnson Services, Inc., United Therapeutics Corp., Teva Pharmaceutical Industries Ltd, Bayer AG, and others.These market players adopt variousstrategies such as product launch, partnerships, collaborations, mergers, and acquisitions to sustain a strong position in the market. For instance, in June 2019 Teva Pharmaceutical Industries Ltd launched a generic version of Tracleer (bosentan) and in May 2019 announced the launch of Letairis (ambrisentan). These drugs indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and delay clinical worsening.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global pulmonary arterial hypertension market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.